PP-089 HBeAg-negative asymptomatic carriers in the drug alone and in combination with the effect of HBV-DNA relationship  by Han, Zu-liang et al.
Poster Presentations S73
PP-087 Hepatitis B virus infection is predominantly
perinatally acquired in the Indian Sub-continent
Hissar Syed*, Manoj Kumar, Kazim Syed Naqvi, Chandana Pande,
Gollapudi Tharun Kumar, Ranjeet Chauhan, Didar Singh, Shiv
Kumar Sarin. G.B. Pant Hospital, New Delhi, India
Background: Hepatitis B Virus (HBV) transmission in India is
presumed predominantly horizontal, but there is scanty data.
We conducted this study to test the hypothesis that chronic
HBV (CHB) infection in India is predominantly due to perinatal
transmission.
Aim: To determine the source of acquisition of HBV infection in
CHB patients.
Patients and Methods: Consecutive patients presenting with
CHB whose relatives consented for evaluation were enrolled and
tested for HBsAg, anti-HBe, anti-HBs and total anti-HBc. Vertical
transmission was deﬁned when the mother was HBsAg positive
or total anti-HBc positive and/or anti-HBe (suggestive of past
exposure). 254 controls were also recruited for comparison.
Results: 476 index patients (Age 25.7±15.6yr; Males 363) had
1274 relatives for screening. In 316 (66.4%) [Age 20.2±14.3yr;
Median (range) = 18 (6mo-58yr); Males 251] index patients, the
mother could be screened. The mothers of 133/316 (42.1%) index
patients were positive for HBsAg and 10/254 (3.9%) controls were
positive for HBsAg (p<0.001). The mothers of 93/316 (29.4%)
index patients were positive only for antibodies (total anti-HBc
and/or anti-HBe) and 2/254 (0.8%) of controls were antibody
positive (p<0.001). 90/316 (28.5%) mothers were negative for
all HBV markers. Of available 56 (17.7%) spouses (M:F::9:47), 25
(44.6%) were antibody positive (anti-HBe and/or total anti-HBc),
4 (7.1%) were HBsAg positive. Of 102 available siblings from 80
(25.3%) families, 27 (26.5%) were found to be antibody positive,
19 (18.6%) were HBsAg+ve.
Conclusions: Nearly 72% of chronic HBV patients in India have
acquired HBV infection through the mother. There is substantial
evidence of present or past HBV infection in mothers of chronic
HBV patients, suggesting possible perinatal transmission.
PP-088 Asymptomatic carriers and chronic hepatitis B
antiviral therapy and efﬁcacy with non-speciﬁc
immune activation of the relationship between
the drug applications
Zu-liang Han*, Yu-sheng Sun, Xin-qi Li. Huang Pu People’s
Hospital, Zhongshan, Guangdong
Objective: To antiviral drugs alone applications and with non-
speciﬁc immune activation of the drug combination treatment,
and explore hepatitis B and chronic hepatitis B virus carriers with
non-speciﬁc immune relationship.
Methods: 255 cases of HBeAg-positive and-negative asymp-
tomatic carriers and chronic hepatitis B were randomly divided
into 2 groups; observation of lamivudine and Mycobacterium FU36
with Chinese medicine group (A group), lamivudine and Chinese
medicine group (B group), HBV-DNA on the efﬁcacy, safety and
efﬁcacy issues, treatment 3 months, 9 month follow-up.
Results: 1. B group of chronic hepatitis B HBV-DNA remarkable
efﬁciency, was signiﬁcantly higher than on the efﬁcacy of asymp-
tomatic carriers, P<0,01. 2. A group of chronic hepatitis B HBV-
DNA remarkable efﬁciency, signiﬁcantly high in the efﬁciency
of B group signiﬁcantly, P<0,01. 3. A group of HBeAg-negative
carriers of asymptomatic HBV-DNA of the signiﬁcant efﬁciency,
signiﬁcantly higher than the B group and HBeAg-positive asymp-
tomatic carriers signiﬁcantly efﬁciency, P<0,01, etc. Course of
treatment has not been any adverse reaction.
Conclusions: Non-speciﬁc immune status changes, and abnormal
alanine aminotransferase, and HBV-DNA was markedly effect the
results signiﬁcantly correlated.
PP-089 HBeAg-negative asymptomatic carriers in the
drug alone and in combination with the effect of
HBV-DNA relationship
Zu-liang Han*, Yu-sheng Sun, Xin-qi Li. Huang Pu People’s
Hospital, Zhongshan, Guangdong
Objective: To drug alone and combined treatment modalities
to explore HBeAg-negative asymptomatic carriers was HBV-DNA
negative effects of selection and treatment of the relationship
between applications.
Methods: Lamivudine and Chinese medicine group (A group), My-
cobacterium phlei FU36 and Chinese medicine group (B group),
and lamivudine and Mycobacterium phlei FU361 and Chinese
medicine group (C group), to liver function and HBV-DNA as the
target effect was observed effects and efﬁcacy of security issues
and so on, three month course of treatment, follow-up 9 months.
Results: 1) C group 31/36 cases (86.11%) HBeAg-negative asymp-
tomatic carriers have HBV-DNA was negative efﬁcacy, signiﬁ-
cantly high in the A group and B group and no case of only
7/23 cases (30.43%) HBV-DNA has a negative effect, P <0,01; 2)
B group has 7/23 cases (30.43%) HBeAg-negative asymptomatic
carriers have HBV-DNA was negative efﬁcacy, signiﬁcantly higher
than the A group and no case showed negative HBV-DNA has the
effect, P <0,01.
Conclusions: Drug alone and combined application of emerging
HBV-DNA the reasons for differences in efﬁcacy, and HBV-DNA
and non-speciﬁc immune response there is existence of “equiv-
alence” relations, and further the formation of each other
"impact" or “constraints” relationship, as well as the efﬁcacy
of existence there is the “dependency” or “complementary
relationship” there is close relationship.
PP-090 Asymptomatic carriers to obtain HBV-DNA
efﬁcacy and drug applications and selectthe
relationship between treatment modalities
Zu-liang Han*, Yu-sheng Sun, Yin-xiang Liu, Xin-qi Li,
Jia-rui Wang. Huang Pu People’s Hospital,Zhongshan,Guangdong
Purpose: Observation of asymptomatic carriers negative HBV-
DNA to obtain the efﬁcacy of the combination drug, the relation-
ship between forms of treatment.
Methods: to 304 cases of asymptomatic carriers were ran-
domly divided into a treatment group and 4 control group;
Lamivudine and the Chinese medicines group (A), lamivudine
and Mycobacterium FU36 and the Chinese medicines group (B),
Mycobacterium FU36 and the Chinese medicines group (C), My-
cobacterium FU 36 and demethylcantharidin tablets with Chinese
medicine group (D), and group B and D turn of the application
of group (treatment group), observation periods of different
treatment on liver function, HBeAg, and HBV-DNA target, such as
the effects of 6-month course of treatment, follow-up 6 months.
Results: 1) HBeAg-positive carriers of asymptomatic, treatment
group has 71.87% and 65.62% have access to HBV-DNA negative
and seroconversion HbeAg efﬁcacy, signiﬁcantly higher than that
of the efﬁcacy of other groups, P <0.01; 2) HBeAg-negative
carriers of asymptomatic, B group and treatment group were
93.10% and79.31% was HBV-DNA negative efﬁcacy, signiﬁcantly
higher than the effect of the other 3 groups, P <0.01, there is no
adverse reaction.
Conclusion: Low non-speciﬁc immune response, HBV-DNA,
HBeAg, as well as speciﬁc immune tolerance to affect the
existence of the cross, as well as the complementary rela-
tionship between efﬁcacy, the formation of the HBeAg-positive
and-negative asymptomatic carriers to obtain HBV-DNA negative
effect of the treatment process and treatment of existence of
the way there is a signiﬁcant difference.
